# Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents

> **NCT06902792** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Second Affiliated Hospital of Wenzhou Medical University** · enrollment: 6 (estimated)

## Conditions studied

- Histiocytosis, Langerhans-Cell

## Interventions

- **DRUG:** treated group

## Key facts

- **NCT ID:** NCT06902792
- **Lead sponsor:** Second Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-02-06
- **Primary completion:** 2025-08-06
- **Final completion:** 2026-02-02
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06902792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06902792, "Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06902792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*